Evidence map›Paper›PMID 40789743›Full record

ArticleJournal for immunotherapy of cancer2025

Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors.

Anthony K Park, Isabel Monroy, Yuwei Ren, Cathy Lu, Shyambabu Chaurasiya, Hannah Valencia, Jackson Lent-Koop, Colin Cook, Seonah Kang, Lupita Lopez and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anthony K ParkDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID http://orcid.org/0000-0001-7692-8874
Isabel MonroyDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Yuwei RenDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Cathy LuDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.ORCID http://orcid.org/0009-0007-0112-4477
Shyambabu ChaurasiyaDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Hannah ValenciaDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Jackson Lent-KoopDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Colin CookDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Seonah KangDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Lupita LopezDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
John P MuradDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Yukiko YamaguchiDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Ryan UrakDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID http://orcid.org/0000-0001-5289-5000
Wen-Chung ChangDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Monil ShahImugene, Sydney, New South Wales, Australia.
Leslie Mi Ok ChongImugene, Sydney, New South Wales, Australia.
Yuman FongDepartment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Xiuli WangDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID http://orcid.org/0000-0001-5964-4327
Saul J PricemanDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA saul.priceman@med.usc.edu.ORCID http://orcid.org/0000-0002-8136-2112

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

backgroundBispecific T cell engager (BiTE), such as blinatumomab, has demonstrated significant clinical success in treating hematological malignancies like B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, the application of BiTEs in solid tumors has proven challenging, primarily due to the lack of targetable tumor antigens and the immunologically "cold" nature of the tumor microenvironment, which limits immune system activation.

methodsWe developed a novel oncolytic virus (OV) platform by engineering a chimeric vaccinia virus to express either a truncated non-signaling CD19 antigen (CD19t) or truncated B cell maturation antigen (BCMAt) on the surface of infected tumor cells. Here, we advance a combinatorial platform using an OV to redirect CD19-targeted or BCMA-targeted T cell engagers (TCEs) to drive antitumor responses against multiple solid tumors.

resultsWe found that OV-infected tumor cells in combination with TCEs significantly improved tumor cell killing against solid tumor models, with efficacy comparable to that of chimeric antigen receptor T cells. This combination approach enhanced antitumor responses using in vivo human tumor xenograft models and promoted more effective elimination of solid tumor cells than either therapy alone. Our studies highlight OVs combined with clinically approved TCEs as a readily translatable, tumor-agnostic, off-the-shelf strategy to effectively target solid tumors.

conclusionsOur findings demonstrate that the combination of OV and TCEs offers a promising strategy to drive antitumor immune responses against solid tumors. This approach represents a novel and universal platform currently in phase 1 clinical trial combining TCE therapy with oncolytic virotherapy, overcoming antigen heterogeneity and immunological barriers for the effective treatment of solid tumors.

Indexed as

ImmunotherapyNeoplasmsOncolytic VirotherapyOncolytic VirusesT-LymphocytesAnimalsCell Line, TumorFemaleHumansMiceXenograft Model Antitumor AssaysBispecific T cell engager - BiTEChimeric antigen receptor - CARCombination therapyImmunotherapyOncolytic virus

Identifiers

PMID40789743
PMCPMC12352182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.